Literature DB >> 29729954

Complement activation in patients with diabetic nephropathy.

X-Q Li1, D-Y Chang1, M Chen2, M-H Zhao1.   

Abstract

AIM: Emerging evidence has indicated a role of the complement system in the pathogenesis of diabetic nephropathy (DN), although the pathways of complement activation and their clinicopathological relevance in DN are as yet unclear. The present study aimed to investigate levels of various complement components in plasma and urine of DN patients, and their correlation with clinicopathological parameters.
METHODS: A total of 68 biopsy-proven DN patients with plasma samples were recruited, including 50 patients who also had urine samples available. Seven complement components (C1q, MBL, Bb, C4d, C3a, C5a, soluble C5b-9) were measured by enzyme-linked immunosorbent assay (Elisa), and any associations between their levels and clinicopathological parameters were then investigated.
RESULTS: In DN patients, plasma levels of C1q, MBL, Bb, C4d, C3a, C5a and sC5b-9 were significantly higher than in diabetes patients without renal involvement, as were also urinary levels except for C1q, which showed no significant differences between the two groups. Also, urinary levels of C3a and C5a were significantly correlated with serum creatinine, urinary protein and estimated glomerular filtration rate, whereas urinary sC5b-9 was significantly correlated with the latter two (and not serum creatinine). In addition, urinary levels of MBL, Bb and C4d were significantly correlated with urinary protein, while C3a, C4d and Bb significantly correlated with the classification of glomerular lesions in DN.
CONCLUSION: In DN patients, the complement system is activated and, of the three possible complement pathways, activation of the lectin and alternative pathways is associated with renal damage.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Complement; Complement activation pathway; Diabetic nephropathy

Mesh:

Substances:

Year:  2018        PMID: 29729954     DOI: 10.1016/j.diabet.2018.04.001

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  25 in total

1.  C3a receptor blockade protects podocytes from injury in diabetic nephropathy.

Authors:  Marina Morigi; Luca Perico; Daniela Corna; Monica Locatelli; Paola Cassis; Claudia Elisa Carminati; Silvia Bolognini; Carlamaria Zoja; Giuseppe Remuzzi; Ariela Benigni; Simona Buelli
Journal:  JCI Insight       Date:  2020-03-12

2.  Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy.

Authors:  Shuang Gao; Zhao Cui; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2022-07-01       Impact factor: 14.978

3.  Proteomic analysis of diabetes genetic risk scores identifies complement C2 and neuropilin-2 as predictors of type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Brian T Steffen; Weihong Tang; Pamela L Lutsey; Ryan T Demmer; Elizabeth Selvin; Kunihiro Matsushita; Alanna C Morrison; Weihua Guan; Mary R Rooney; Faye L Norby; Nathan Pankratz; David Couper; James S Pankow
Journal:  Diabetologia       Date:  2022-10-04       Impact factor: 10.460

4.  Pathological significance of urinary complement activation in diabetic nephropathy: A full view from the development of the disease.

Authors:  Jing-Min Zheng; Zuan-Hong Jiang; De-Jun Chen; Sa-Sa Wang; Wen-Jin Zhao; Li-Juan Li
Journal:  J Diabetes Investig       Date:  2018-10-13       Impact factor: 4.232

5.  Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy.

Authors:  Karyne Pelletier; Arnaud Bonnefoy; Hugo Chapdelaine; Vincent Pichette; Matthieu Lejars; François Madore; Soumeya Brachemi; Stéphan Troyanov
Journal:  Kidney Int Rep       Date:  2019-03-20

6.  Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Authors:  Elisabetta Valoti; Marina Noris; Annalisa Perna; Erica Rurali; Giulia Gherardi; Matteo Breno; Aneliya Parvanova Ilieva; Ilian Petrov Iliev; Antonio Bossi; Roberto Trevisan; Alessandro Roberto Dodesini; Silvia Ferrari; Nadia Stucchi; Ariela Benigni; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Front Genet       Date:  2019-07-26       Impact factor: 4.599

7.  Investigation of the Mechanism of Complement System in Diabetic Nephropathy via Bioinformatics Analysis.

Authors:  Bojun Xu; Lei Wang; Huakui Zhan; Liangbin Zhao; Yuehan Wang; Meng Shen; Keyang Xu; Li Li; Xu Luo; Shasha Zhou; Anqi Tang; Gang Liu; Lu Song; Yan Li
Journal:  J Diabetes Res       Date:  2021-05-24       Impact factor: 4.011

8.  Identification of C3 as a therapeutic target for diabetic nephropathy by bioinformatics analysis.

Authors:  ShuMei Tang; XiuFen Wang; TianCi Deng; HuiPeng Ge; XiangCheng Xiao
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

9.  Deficiency of C3a receptor attenuates the development of diabetic nephropathy.

Authors:  Xiao-Qian Li; Dong-Yuan Chang; Min Chen; Ming-Hui Zhao
Journal:  BMJ Open Diabetes Res Care       Date:  2019-11-15

10.  Association of Glomerular Complement C4c Deposition With the Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes.

Authors:  Suyan Duan; Lianqin Sun; Guangyan Nie; Jiajia Chen; Chengning Zhang; Huanhuan Zhu; Zhimin Huang; Jun Qian; Xiufen Zhao; Changying Xing; Bo Zhang; Yanggang Yuan
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.